Molecular testing of lung cancer in Australia: consensus best practice recommendations from the Royal College of Pathologists of Australasia in collaboration with the Thoracic Oncology Group of Australasia.

IF 3.6 3区 医学 Q1 PATHOLOGY
Wendy A Cooper, Benhur Amanuel, Caroline Cooper, Stephen B Fox, Jon W A Graftdyk, Peter Jessup, Sonja Klebe, Wei-Sen Lam, Trishe Y-M Leong, Zarnie Lwin, Rachel Roberts-Thomson, Benjamin J Solomon, Rebecca Y Tay, Rebecca Trowman, Janney L Wale, Nick Pavlakis
{"title":"Molecular testing of lung cancer in Australia: consensus best practice recommendations from the Royal College of Pathologists of Australasia in collaboration with the Thoracic Oncology Group of Australasia.","authors":"Wendy A Cooper, Benhur Amanuel, Caroline Cooper, Stephen B Fox, Jon W A Graftdyk, Peter Jessup, Sonja Klebe, Wei-Sen Lam, Trishe Y-M Leong, Zarnie Lwin, Rachel Roberts-Thomson, Benjamin J Solomon, Rebecca Y Tay, Rebecca Trowman, Janney L Wale, Nick Pavlakis","doi":"10.1016/j.pathol.2025.02.001","DOIUrl":null,"url":null,"abstract":"<p><p>Molecular testing plays a critical role in guiding optimal treatment decisions for lung cancer patients across a variety of clinical settings. While guidelines for biomarker testing exist in other jurisdictions, to date no best practice guidelines have been developed for the Australian setting. To address this need, the Royal College of Pathologists of Australasia collaborated with the Thoracic Oncology Group of Australasia to identify state-based pathologists, oncologists and consumer representatives to develop consensus best practice recommendations. Sixteen recommendations were established encompassing appropriate biomarkers, lung cancer subtype, tumour stage, specimen types, assay selection and quality assurance protocols that can inform and standardise best practice in molecular testing of lung cancer. These multidisciplinary evidence-based recommendations are designed to standardise and enhance molecular testing practices for lung cancers and should help ensure laboratories provide high-quality molecular testing of lung cancer for all Australians, including those from regional or remote communities.</p>","PeriodicalId":19915,"journal":{"name":"Pathology","volume":" ","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.pathol.2025.02.001","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Molecular testing plays a critical role in guiding optimal treatment decisions for lung cancer patients across a variety of clinical settings. While guidelines for biomarker testing exist in other jurisdictions, to date no best practice guidelines have been developed for the Australian setting. To address this need, the Royal College of Pathologists of Australasia collaborated with the Thoracic Oncology Group of Australasia to identify state-based pathologists, oncologists and consumer representatives to develop consensus best practice recommendations. Sixteen recommendations were established encompassing appropriate biomarkers, lung cancer subtype, tumour stage, specimen types, assay selection and quality assurance protocols that can inform and standardise best practice in molecular testing of lung cancer. These multidisciplinary evidence-based recommendations are designed to standardise and enhance molecular testing practices for lung cancers and should help ensure laboratories provide high-quality molecular testing of lung cancer for all Australians, including those from regional or remote communities.

澳大利亚肺癌分子检测:澳大拉西亚皇家病理学家学院与澳大拉西亚胸部肿瘤学小组合作的共识最佳实践建议。
分子检测在指导各种临床环境下肺癌患者的最佳治疗决策方面发挥着关键作用。虽然其他司法管辖区存在生物标志物检测指南,但迄今为止尚未为澳大利亚制定最佳实践指南。为了满足这一需求,澳大拉西亚皇家病理学家学院与澳大拉西亚胸部肿瘤学小组合作,确定各州的病理学家、肿瘤学家和消费者代表,以制定共识的最佳实践建议。制定了16项建议,包括适当的生物标志物、肺癌亚型、肿瘤分期、标本类型、测定方法选择和质量保证方案,可为肺癌分子检测的最佳实践提供信息和标准化。这些多学科循证建议旨在标准化和加强肺癌分子检测实践,并应有助于确保实验室为所有澳大利亚人提供高质量的肺癌分子检测,包括来自地区或偏远社区的人。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pathology
Pathology 医学-病理学
CiteScore
6.50
自引率
2.20%
发文量
459
审稿时长
54 days
期刊介绍: Published by Elsevier from 2016 Pathology is the official journal of the Royal College of Pathologists of Australasia (RCPA). It is committed to publishing peer-reviewed, original articles related to the science of pathology in its broadest sense, including anatomical pathology, chemical pathology and biochemistry, cytopathology, experimental pathology, forensic pathology and morbid anatomy, genetics, haematology, immunology and immunopathology, microbiology and molecular pathology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信